Physician profile
Ka Blia Lo
NPI 1447878194
$2,374.86
in general payments reported to CMS, 2019-2025
19 companies · $983 in 2025
The $983 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $451 · 2023: $106 · 2024: $357 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.31 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,285.32 | 2022-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $400.23 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.20 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.95 | 2021-2022 | |
| Amarin Pharma, INC. | $69.70 | 2021 | |
| Currax Pharmaceuticals LLC | $45.18 | 2024-2025 | Contrave |
| Astrazeneca Pharmaceuticals LP | $45.13 | 2021-2022 | |
| Amgen INC. | $36.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.12 | 2022 | |
| Merck Sharp & Dohme LLC | $31.70 | 2022 | |
| Esperion Therapeutics, INC. | $23.95 | 2021 | |
| Eisai INC. | $20.49 | 2022 | |
| Edwards Lifesciences Corporation | $19.83 | 2022 | |
| Hikma Pharmaceuticals USA | $17.32 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.32 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.67 | 2021 | |
| Seqirus USA INC | $14.72 | 2021 | |
| Glaxosmithkline, LLC. | $14.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ka Blia Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.